ChemoStabilityChart 1sep06 Rev2 PDF

DRUG & STRENGTH
(Storage Prior to Use,

Manufacturer, Presevative
Status)
Aldesleukin
22 million IU
(1.3 mg)
(Chiron)
(F)(PFL)
no preservative1
Alemtuzumab
30 mg/3 mL
(Schering/Ilex)
(F)(PFL)
do not shake
no preservative5
Amifostine
500 mg
(MedImmune)
(RT)
no preservative10
B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
do not shake; roll

to reconstitute1
18 million IU/mL1
(1.1 mg/mL)
48 h F, RT1
1.2 mL SWI only1
N/A
10 mg/mL
9.7 mL NS only10
48 h F, RT1
- cytotoxic3
- overfill not known
- do not filter
- nonvesicant4
- latex** content
not determined
SC syringe7
8 h F or RT6
100 mL NS or D5W5
8 h F or RT6
- cytotoxic3
- do not shake6
- protect from light6
- nonvesicant8
- latex-free9
2550 mL* NS only10
540 mg/mL:
24 h F,10 5 h RT
3070 mcg/mL1
50 mL D5W only1
< 30 mcg/mL: dilute
only in D5W that
contains human
albumin 0.1%2
use 5 micron filter to

withdraw drug from
ampoule6
discard unused
portion5
50 mg/mL10
BC Cancer Agency Chemotherapy Preparation and Stability Chart

Activation Date: 2 March 2006
Revised Date: 29 August 2006
24 h F, 5 h RT10
Special
Precautions/Notes
1/33
- noncytotoxic10
- discard cloudy
solution2
- nonvesicant4
- latex** content
not determined
DRUG & STRENGTH

Status)
Amsacrine
75 mg/1.5 mL
(Pfizer)
(RT)
no preservative1

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
glass syringes
preferred during
reconstitution
- max time in
plastic syringe:
15 min1
5 mg/mL1
24 h RT1
500 mL D5W only1

glass container
72 h F, 24 h RT1
2500 units/mL13
24 h F13
syringe13
14 d F13
Special
Precautions/Notes
- cytotoxic3
- vesicant11
- contains latex**12
13.5 mL supplied
diluent1
transfer 1.5mL
from ampoule
into the diluent
vial
L-Asparaginase13
(asparaginase E. coli)
10,000 units
(OPi)
(F)
do not shake; roll

to reconstitute1,2
4 mL SWI13

2/33
- cytotoxic3
- overfill14
- nonvesicant11
- latex-free**9
DRUG & STRENGTH

Status)
no preservative14

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
Intradermal
test2:
Reconstitute
with 5 mL
SWI to give
2000
units/mL
Transfer 0.1
mL to 10 mL
vial (or 12 mL
syringe)
Add 9.9 mL
SWI roll to
dissolve to
give 20
units/mL
2 unit test
dose = 0.1
mL
(Note: the rest of
the reconstituted
vial has a
concentration of
2000 units/mL)

50 mL* NS or
15,16
D5W
14 d F, 15,16 2 d RT16,17
3/33
Special
Precautions/Notes
DRUG & STRENGTH

Status)
BCG
81 mg
(Aventis Pasteur)
(F)(PFL)
preservative1

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
do not shake; roll

to reconstitute18
10.5 8.7108
CFU/vial (Connaught
strain)1
2 h F, RT1
50 mL NS1
2 h F or RT after
reconstitution1
- cytotoxic3
- protect from
light18
- nonvesicant11
- latex** content
not determined
1-8108 CFU/vial
(TICE strain)1
2 h F19
transfer from vial to

50 mL syringe, rinse
vial with another 1
mL NS. Add rinse to
50 mL syinge. QS
syringe to 50 mL with
NS1
2 h F after
reconstitution19
- cytotoxic3
- protect from
light19
- do not filter
- nonvesicant11
- latex-free**9
25 mg/mL20
discard unused
portion20
100 mL NS only20
48 h F, RT17,20
- cytotoxic3
- do not shake20
- nonvesicant11
- latex** content
not determined
3 mL supplied
diluent1
record time of
reconstitution
BCG
(Organon)
(F)(PFL)
no preservative1
do not shake; roll

to reconstitute19
1 mL NS1
record time of
reconstitution
Bevacizumab
100 mg/4 mL
400 mg/16 mL
(Roche)
(F)(PFL)
do not shake20
no preservative20
N/A
Special
Precautions/Notes

4/33
DRUG & STRENGTH

Status)
Bleomycin
15 IU
(NB: dose in units only)
(Bristol)
(F)
no preservative21
Bleomycin
15 IU
(NB: dose in units only)
(Mayne)
(F)(PFL)22
no preservative1
Bortezomib
3.5 mg
(Millennium)
(RT)(PFL)
no preservative25
Busulfan
60 mg/10 mL
(Orphan Medical)
(F)
no preservative29

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
Special
Precautions/Notes
6 mL* NS21
2.5* IU/mL
48 h F21
50 mL* NS21
NS: 24 h RT21
- cytotoxic3
- nonvesicant11
- latex** content
not determined
6 mL* NS or
SWI22
2.5* IU/mL22
48 h F, 24 h RT
50 mL* NS, SWI22
24 h RT23
- cytotoxic3
- nonvesicant11
- latex-free24
3.5 mL NS25
1 mg/mL25
2d RT26,27
syringe25
8 h RT28
- cytotoxic3
- irritant4
- latex** content
not determined
N/A
use 5-micron nylon

filter provided with
ampoule to withdraw
drug29
discard unused
portion29
NS or D5W (dilute in
volume 10 times the
busulfan volume to ~
0.5 mg/mL)29
12 h F: NS29
8 h RT: NS, D5W
- cytotoxic3
- vesicant11
- latex** content
not determined
discard unused
portion30
may be further
diluted up to 0.3-2
mg/mL
48 h F30
- cytotoxic3
- nonvesicant11
- latex** content
not determined
22
6 mg/mL29
Carboplatin
50 mg/5 mL
150 mg/15 mL
450 mg/45 mL
(Mayne Pharma)
(RT)(PFL)
no preservative30
N/A
10 mg/mL30

250 mL* NS, D5W2,30
5/33
DRUG & STRENGTH

Status)
Carboplatin
50 mg/5 mL
150 mg/15 mL
450 mg/45 mL
(Novopharm)
(RT)(PFL)
no preservative31
Carmustine
100 mg
(Bristol Labs)
(F)
no preservative33
Cetuximab
100 mg/50 mL
(BMS)
(F)
do not dilute35
do not shake35
no preservative35

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
10 mg/mL31
8 h RT31
8 h RT31
may be further diluted

to 0.5 mg/mL31,32
Special
Precautions/Notes
- cytotoxic3
- nonvesicant11
- latex-free**9
250 mL* NS,

D5W2,31,32
3 mL diluent
(supplied)33
3.3 mg/mL in 10%

ethanol33
24 h F, 8 h RT 33
500 mL NS or D5W33
diluent to reach
RT, then dissolve
drug with 3 mL
diluent;
add 27 mL SWI33
N/A
glass,33 or polyolefin
container2
33
24 h F: in glass, or
polyolefin container2
use within 4 hours of
reconstitution RT16,33
2 mg/mL35

discard unused
portion35
syringe35
12 h F, 8 h RT35
6/33
- cytotoxic3
- do not use if
product has oily
droplets33
- vesicant11
- latex** in diluent
stopper9,34
- no latex** in
product stopper or
drug product34
- cytotoxic3
- do not shake35
- use 0.22 micron
in-line filter to
administer
- nonvesicant 4
- latex** content
not determined
DRUG & STRENGTH

Status)
Cisplatin
10 mg/10 mL
50 mg/50 mL
100 mg/100mL
(Mayne)
(RT)(PFL)
no preservative36
Cladribine
10 mg/10 mL
(Janssen-Ortho)
(F)(PFL)
no preservative40
Clodronate
300 mg/10 mL
(Oryx)
(RT)
no preservative41

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
1 mg/mL36
48 h RT37
Special
Precautions/Notes
sterile evacuated
container e.g., glass
bottle, polyolefin bag,
ethylene vinyl acetate
bag, DEHP
plasticized PVC bag,
or PVC bag35
12 h F, 8 h RT,35
< 60 mg: 100 NS*

> 60 mg: 250 NS*
48 h RT37
- cytotoxic3
- irritant11
- latex stoppers39
500 or 1000 mL* NS,

D5-NS, D5-1/2S; D5NS with mannitol; D51/2S with
mannitol36,38; D5W1/3S with mannitol36
N/A
1 mg/mL40
discard unused
portion40
500 mL NS only40
24 h RT40
- cytotoxic3
- shake vigorously
to dissolve any
precipitates from
refrigeration2
- nonvesicant11
- protect from
light40
- latex-free**9
N/A
30 mg/mL
discard unused
portion41
500 mL NS or D5W41
12 h RT41
- noncytotoxic
- nonvesicant11
- latex** content
not determined

7/33
DRUG & STRENGTH

Status)
Cyclophosphamide
non-lyophilized
1000 mg
2000 mg
(BMS)
(RT)
no preservative42
Cyclophosphamide
200 mg
500 mg
1000 mg
2000 mg
(Baxter)
(RT)(PFL)
no preservative43
Cytarabine
100 mg/1 mL
500 mg/5mL
1000 mg/10mL
2000 mg/20mL
(Mayne)
(RT)
no preservative46

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
SWI42
20 mg/mL42
48 h F, 24 h
RT16,42
1000 mg: 50 mL
2000 mg: 100 mL
< 1 g: 100 NS*

> 1 g: 250 NS*
high dose in BMT:
may need 500 NS*
6 d F, 24 h RT42
Special
Precautions/Notes
- cytotoxic3
- nonvesicant11
- latex-free**9,34
NS,2 D5W, D5NS,

D5, Ringers,
Lactated Ringers,
Sodium Chloride
0.45%, Sodium
Lactate42
NS43
20 mg/mL43
48 h F,27,43,44 24
RT45
200 mg: 10 mL
500 mg: 25 mL
1000 mg: 50 mL
2000 mg: 100
mL43
N/A
< 1 g: 100 NS*

> 1 g: 250 NS*
high dose in BMT:
may need 500 NS*
48 h F,27,43 24 h RT43
- cytotoxic3
- nonvesicant11
- latex** content
not determined
72 h F, 24 h RT from
initial vial puncture46
- cytotoxic3
- nonvesicant11
- latex stopper**48
NS,2 D5W, D5NS43

100 mg/mL46
record time of
punture

24 h RT46
0.1-0.8 mg/mL47
100 mL* NS, Water
for Injection, D5W,
Lactated Ringers
8/33
DRUG & STRENGTH

Status)
Cytarabine
IT injection46:
100 mg/1 mL
500 mg/5 mL
1000 mg/10mL
2000 mg/20mL
(Mayne)
(RT)
no preservative46
Cytarabine
SC injection:
100 mg
1000 mg
vial
(Pfizer)
(RT)(PFL)
no preservative1
Cytarabine
SC injection:
100 mg
500 mg
1000 mg
2000 mg
vial
(Novopharm)
(RT)(PFL)
no preservative31

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
100 mg/mL46
24 h RT46
diluents containing
preservatives should
NOT be used for
intrathecal
administration46

initial puncture2,16
- cytotoxic3
- auxiliary label50:
IT
- label to include
route in full (i.e.,
INTRATHECAL
injection) atttached
to both syringe and
outer ziplock bag50
- nonvesicant11
- latex stopper**48
qs to 6 mL with
preservative free
NS49
100 mg: 5 mL
BWI1
100 mg:
20 mg/mL1
1 g: 10 mL BWI1
1000 mg:
100 mg/mL1
BWI31
100 mg: 20 mg/mL

500 mg: 50 mg/mL
1000 mg: 100 mg/mL
2000 mg: 100 mg/mL
100 mg: 5 mL
500 mg: 10 mL
1000 mg: 10 mL
2000 mg: 20 mL
48 h RT51
syringe
14 d F, 48 h RT51
- cytotoxic3
- for high dose
use, do not use
diluent containing
benzyl alcohol31
-overfill not known
- nonvesicant11
- latex-free**9
48 h F, RT16,31
syringe
14 d F, 48 h RT2,16,17
- cytotoxic3
- for high dose
use, do not use
diluent containing
benzyl alcohol31
- nonvesicant11
- latex** content
not determined
31

Special
Precautions/Notes
9/33
DRUG & STRENGTH

Status)
Dacarbazine
200 mg
600 mg
(Mayne)
(F)(PFL)
no preservative52

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
200 mg: 19.7 mL

SWI52
600 mg: 59.1 mL
SWI
10 mg/mL52
48 h F,16,53 8 h
RT53
(PFL)54
0.193.0 mg/mL52
24 h F52
- cytotoxic3
- protect from
light54
- no overfill54
- irritant11
- latex stopper**9,48
syringe52
24 h F, RT16,56
infusion: 50 mL*
D5W, NS2,16,53
24 h F, RT56
- cytotoxic3
- do not filter2
- vesicant11
- latex-free**57
100-250 mL
NS or D5W2
48 h F, 24 h RT31
empty viaflex bag59
6 h RT60
500 mL* NS or D5W
(may use
reconstitution
device)
Dactinomycin
0.5 mg
(Merck Frost)
(RT)(PFL)
no preservative55
Daunorubicin
20 mg
(Novopharm)
(RT)(PFL)
no preservative31
Dexrazoxane
250 mg
500 mg
(Pfizer)
(RT)
no preservative59
1.1 mL SWI55
4 mL SWI31
0.5 mg/mL55
(500 mcg/mL)
5 mg/mL31
24 h F, RT56
24 h RT, 48 h F31
(PFL)31
supplied diluent
59
:
250 mg: 25 mL
500 mg: 50 mL
10 mg/mL59
6 h F59
(may use
reconstitution
device)

Special
Precautions/Notes
10/33
- cytotoxic3
- vesicant11
- latex-free**9,58
- cytotoxic61
- no overfill61
- nonvesicant4
- latex-free**9,62
DRUG & STRENGTH

Status)
Docetaxel
20 mg/0.5 mL
80 mg/2 mL
(Aventis)
(PFL)
no preservative63
Doxorubicin
10 mg
50 mg
150 mg
(Mayne)
(RT)(PFL)
no preservative64
Doxorubicin
10 mg/5 mL
20 mg/10 mL
50 mg/25 mL
200 mg/100 mL
(Novopharm)
(F)(PFL)
no preservative67

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
supplied diluent :
- if vials were
refrigerated, allow
to warm for 5 min
at RT. Withdraw
entire contents of
the diluent and
mix by repeated
inversions for 45
sec DO NOT
SHAKE. - Let sit
63
for 5 minutes.
10 mg/mL63
NS, SWI, D5W64

(NS reconstitution
takes longer)
10 mg: 5 mL
50 mg: 25 mL
150 mg: 75 mL
2 mg/mL64
N/A
2 mg/mL
8 h F, RT63
0.30.74 mg/mL
4 h F, RT63
(e.g., 250 mL NS or
D5W)63
48 h F, 24 h RT,
16,64
syringe64
48 h F, 24 h RT16,65
0.22 mg/mL66
48 h F, 24 h RT16,66
Special
Precautions/Notes
- cytotoxic3
- non-PVC bag
and tubing only63
- overfill63
- irritant11
- latex-free**9
- cytotoxic3
- vesicant11
100 mL* NS64

8 h RT67
syringe67
48 h F, 24 h RT67
11/33
- cytotoxic3
- vesicant11
- latex** content
not determined
DRUG & STRENGTH

Status)
Doxorubicin
Pegylated Liposomal
20 mg/10 mL
50 mg/25 mL
(Schering)
(F)
no preservative68
Epirubicin
10 mg/5 mL
50 mg/25 mL
200 mg/100 mL
(Pfizer)
(F)(PFL)
no preservative69
Etoposide
100 mg/5 mL
500 mg/25 mL
1000 mg/50 mL
(BMS)
(RT)
preservative70

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
2 mg/mL68
discard unused
portion68
24 h F68
- cytotoxic3
- do not filter68
- vesicant11
- latex-free**9
syringe69
48 h F, 24 h RT from
initial vial puncture69
- cytotoxic3
- vesicant11
- latex-free**9
100 mL* NS or D5W2
2 d F, RT: NS or
D5W16,37
0.2 0.4 mg/mL70
0.2 mg/mL: 96 h RT70

0.4 mg/mL: 24 h RT70
< 90 mg: 250 mL

D5W only68
90 mg: 500mL D5W
only
N/A
2 mg/mL69
8 h F, RT69
record time of
puncture
N/A
20 mg/mL70

14 h RT16,71
Special
Precautions/Notes
500 mL* NS or
D5W70
12/33
- cytotoxic3
- use non-PVC bag
and tubing only
- irritant11
- latex** content
not determined
DRUG & STRENGTH

Status)
Etoposide
100 mg/5 mL
200 mg/10 mL
500 mg/25 mL
1000 mg/50 mL
(Novopharm)
(RT)(PFL)
no preservative72
Fludarabine
50 mg
(Berlex)
(F)
no preservative73
Fluorouracil
5000 mg/100 mL
(Mayne)
(RT)(PFL)
no preservative74

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
20 mg/mL72
discard unused
portion72
max. 0.4 mg/mL72
4 h RT27,72
- cytotoxic3
- use non-PVC bag
and tubing only
- irritant11
- latex** content
not determined
48 h F, RT16,37
- cytotoxic3
-overfill not known
- nonvesicant11
- latex-free**9
syringe16
48 h RT16,17,48

to 2 mg/mL in
D5W48,74
24 h RT48,74
- cytotoxic3
- irritant11
- latex-free**54
500 mL* NS or
D5W72
2 mL SWI73
25 mg/mL73
48 h F or RT16,37

to 1 mg/mL73
100 mL* NS or
D5W73
N/A
50 mg/mL74
8 h RT48,74
50-1000 mL* D5W
CIVI: ambulatory
pump48

Special
Precautions/Notes
complete within 8
2,75,76
d
13/33
DRUG & STRENGTH

Status)
Gemcitabine
200 mg
1000 m g
(Eli-Lilly)
(RT)
no preservative77
Idarubicin
5 mg
10 mg
(Pfizer)
(RT)(PFL)
no preservative79
Ifosfamide
1000 m g
3000 mg
(Baxter)
(RT)2
no preservative82

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
200 mg: 5 mL NS
1000 mg: 25 mL
NS77
38 mg/mL77
48 h RT78
(may use
reconstitution
device)
vial under
negative
pressure79
Interferon Alfa -2b

25 million IU/2.5 mL
(Schering)
(F)(or up to 7 days at
48 h RT16,78
0.110 mg/mL77,78
48 h F, RT16,78
- cytotoxic3
- no overfill78
- nonvesicant11
- latex-free**9,78
250 mL NS*
1 mg/mL79
48 h F,79 24 h
RT,
(PFL)79
syringe
48 h F,79,80 24 h RT16
(PFL)79
- cytotoxic3
- vesicant11
- latex-free**81
50 mg/mL82
72 h F82
0.620 mg/mL82
72 h F82
5001000 mL* NS,

D5W, D5-NS,
D5-1/2NS, Lactated
Ringers2,82
24 h F, RT when
mixed with mesna2
- cytotoxic3
- nonvesicant11
- latex-free**9
5 mg: 5 mL SWI
10 mg: 10 mL
SWI79
1000 mg: 20 mL
SWI82
3000 mg: 60 mL
SWI
shake well
Interferon Alfa -2b

18 million IU/3 mL
(Schering)
(F)(or up to 7 days at
RT before use)
no preservative83
syringe77
Special
Precautions/Notes
N/A
6 million IU/mL83
48 h F16,83
D5W or Lactated
Ringers when mixed
syringe83
2 d F16,84
0.3 million IU/mL83
24 h F, RT84
- cytotoxic3
- overfill83
- nonvesicant11
- latex-free**9,84
50 mL NS83
N/A
10 million IU/mL83

48 h F16,83
syringe83
2 d F16,84
14/33
- cytotoxic3
- overfill83
- nonvesicant11
DRUG & STRENGTH

Status)
RT before use)
no preservative83

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
0.3 million IU/mL
83
84
Special
Precautions/Notes
- latex-free**9,84
24 h F, RT
50 mL NS83
Interferon Alfa -2b
10 million IU
(Schering)
(F)
no preservative83
1 mL supplied
diluent (SWI) 83
10 million IU/mL83
24 h F83
do not shake; roll

to reconstitute83
syringe83
24 h F, RT84
> 0.1 million IU/mL85
48 h RT2,16
- cytotoxic3
- overfill83
-nonvesicant11
- latex-free**9,84
100 mL NS86
1 mL BWI83
48 h F, RT16,83
do not shake; roll

to reconstitute83
Interferon Alfa -2b
18 million IU
(Schering)
(F)
no preservative83
1 mL supplied
diluent 83
18 million IU/mL83
24 h F83
do not shake; roll

to reconstitute83
syringe86
14 d F, 48 h RT16,86
100 mL NS86
48 h RT2,16
syringe83
24 h F, RT84
> 0.1 million IU/mL85
48 h RT2,16
100 mL NS86
1 mL BWI83
do not shake; roll
to reconstitute83

48 h F, RT16
syringe83
14 d F16,86
100 mL NS86
48 h RT2,16
15/33
- cytotoxic3
- overfill83
- nonvesicant11
- latex-free**9,84
DRUG & STRENGTH

Status)
Irinotecan
40 mg/2 mL
100 mg/5 mL
500 mg/25 mL
(Mayne)
(RT)(PFL)
no preservative87
Irinotecan
40 mg/2 mL
100 mg/5 mL
(Pfizer)
(RT)(PFL)
no preservative89
Leucovorin
50 mg/5 mL
500 mg/50 mL
(Mayne)
(F)(PFL)
no preservative90
Mechlorethamine
10 mg
(Merck)
no preservative92

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
N/A
N/A
do NOT use if
discoloured or
water droplets
20 mg/mL87
20 mg/mL89
10 mg/mL90
1 mg/mL92

2 days RT27,88
0.12 2.8 mg/mL87
24 h RT: D5W, NS87
500 mL2 D5W

(preferred), NS87
48 h F: D5W
(PFL)87
0.12 2.8 mg/mL89
24 h RT: D5W, NS89
500 mL2 D5W

(preferred), NS89
48 h F: D5W
(PFL)89
5 mL vial: discard
unused portion90
syringe91
48 h F91
50 mL vial: 8 h F,
RT

to 0.05 mg/mL90
24 h RT90: NS, D5W,

Lactated Ringers,
Ringers
50-250 mL* NS,

D5W, Lactated
Ringers, Ringers,
D10W, D5-NS
8 h RT90: D10W, D5NS
discard unused
portion89
use within 4
hours of
reconstitution
syringe92

reconstitution RT16,37,92
16/33
Special
Precautions/Notes
- cytotoxic3
- do NOT
refrigerate if in
NS89
- nonvesicant11
- latex** content
not determined
- cytotoxic3
- do NOT
refrigerate if in
NS89
- nonvesicant11
- latex-free**9
- noncytotoxic
- nonvesicant11
- latex-free**48
- cytotoxic3
- vesicant11
DRUG & STRENGTH

Status)

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
RT2,80
form in vial before

reconstitution2
100 mL NS2

reconstitution RT16,37,92
Special
Precautions/Notes
- latex** content
not determined
10 mL SWI or
NS92
Medroxyprogesterone
250 mg/5 mL
(Pfizer)
(RT)
preservative1
Medroxyprogesterone
Depo
150 mg/1mL
(Pfizer)
(RT)
preservative1
Melphalan
50 mg
(GSK)
(RT)(PFL)
no preservative93
N/A
50 mg/mL1
use within 4
hours of initial
puncture1,16
syringe: IM only1

- cytotoxic3
- auxiliary label:
shake before use1- nonvesicant4
- latex-free**9
N/A
150 mg/mL1
use within 4
hours of initial
puncture1,16
syringe: IM only1

- cytotoxic3
- auxiliary label:
shake before use1
- nonvesicant4
- latex-free**9
10mL supplied
diluent 93
5 mg/mL93
2 h RT93
0.1 0.45 mg/mL in

NS only
1 h RT from time of
initial reconstitution2
- cytotoxic3
- vesicant11
- latex-free**94
immediately after
adding diluent,
shake
vigorously93
do NOT
refrigerate
(e.g., >45 mg and <

110 mg in 250 mL
NS)*
record time of
reconstitution

17/33
DRUG & STRENGTH

Status)
Mesna
1000 mg/10mL
(PPC)
(RT)
preservative95
Methotrexate
50 mg/2mL
500 mg/20mL
1 g/40mL
5 g/200mL
(Mayne)
(RT)(PFL)
no preservative52

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
100 mg/mL95
14 d F, RT16,95
> 1mg/mL95
48 h F, 24 h RT95
NS or D5W
N/A
25 mg/mL52
50mg: discard
unused portion52
500mg, 1 g mL, 5
g mL: 8 h F, RT52
syringe
2 d F, RT2,96,97
0.42 mg/mL52
24 h RT52
100 mL*
NS, D5W
Special
Precautions/Notes
- noncytotoxic
- nonvesicant
(diluted)11
- irritant
(undiluted)11
- latex** content
not determined
- cytotoxic3
- for high-dose
regimens (e.g., 1-8
mg/m2 as a single
dose)98-101 use
preservative-free
methotrexate2
- nonvesicant11
- latex-free**48
high dose(e.g., 1-8

mg/m2 as a single
dose)98-101: 5001000
mL*
Methotrexate
IT Injection52:
Only preservative free
methotrexate may be
administered by the
intrathecal route52
20 mg/2mL
(Mayne)
(RT)(PFL)
no preservative52
N/A
10 mg/mL52

discard unused
portion52
qs to 6 mL with
preservative free
NS49

18/33
- cytotoxic3
- auxiliary label50:
IT
- label to include
INTRATHECAL
to both syringe and
outer ziplock bag50
- nonvesicant11
- latex-free**48
DRUG & STRENGTH

Status)
Methotrexate
50 mg/2mL
500 mg/20mL
(Mayne)
(RT)(PFL)
preservative52

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
25 mg/mL52
24 h F96
syringe
7 d F2,96,97
0.42 mg/mL52
24 h RT52
e.g., 100 mL* NS,

D5W52
Mitomycin
5 mg
20 mg
(Novopharm)
(RT)(PFL)
no preservative31
SWI
5 mg: 10 mL
20 mg: 40 mL
0.5 mg/mL31
48 h F, RT16,31
syringe2,16
(PFL)31
shake well31
0.02-0.04 mg/mL
50 mL* NS, D5W,
sodium lactate
31
Mitomycin
5 mg
20 mg
(BMS)
(RT)(PFL)
no preservative103
14 d F, 48 h RT2,16,17
SWI
5 mg: 10 mL
20 mg: 40 mL
0.5 mg/mL103
48 h F, RT16,103
syringe2
0.020.04 mg/mL
(may use
reconstitution
device)
50 mL* NS, D5W,

sodium lactate103

- cytotoxic3
- high-dose
regimen(e.g., 1-8
mg/m2 as a single
dose) 98-101: use
preservative-free
methotrexate2
- nonvesicant11
- latex-free**9,48
- cytotoxic3
- vesicant11
- latex-free**
(stopper or
product)9,102
3 h RT: D5W
12 h RT: NS
24 h RT: sodium
lactate31
14 d F, 48 h RT2,17
(PFL)31
shake well103
Special
Precautions/Notes
12 h RT: NS
3h: D5W
24 h: sodium lactate103
19/33
- cytotoxic3
- no overfill102
- vesicant11
DRUG & STRENGTH

Status)
Mitoxantrone
20 mg/10 mL
25 mg/12.5 mL
(Wyeth)
(RT)(PFL)
no preservative104
Mitoxantrone
20 mg/10mL
(Mayne)
(RT)(PFL)
no preservative105

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
2 mg/mL104
discard unused
portion104
NS, D5W104
24 h RT104
50 mL*
N/A
2 mg/mL105
discard unused
portion105
0.2-0.6 mg/mL53
NS: 24 h F, RT
NS, D5W105
D5W: 72 h F, 24 h
RT105
50 mL*
Octreotide
(Sandostatin)
1000 mcg/5 mL
(Novartis)
(F)(PFL)
preservative1
Octreotide
(Sandostatin)
50 mcg/1 mL
100 mcg/1 mL
500 mcg/1 mL
(Novartis)
(F)(PFL)
no preservative1
N/A
200 mcg/mL1
discard unused
portion106
50200 mL NS1
2,107
Special
Precautions/Notes
- cytotoxic3
- protect from light
- irritant11
- latex** content
not determined
- cytotoxic3
- protect from
light53
- irritant11
- latex-free**9
24 h RT1
- noncytotoxic10
- nonvesicant11
- latex-free**9
24 h RT1
- noncytotoxic10
- nonvesicant11
- latex-free9
SC infusion: adjust
volume to ensure
infusion rate of 25
mcg/h1
N/A
50 mcg/mL
100 mcg/mL
500 mcg/mL1

discard unused
portion1
50-100 mL2,107
NS1
SC infusion: adjust
volume to ensure
infusion rate of 25
mcg/h1
20/33
DRUG & STRENGTH

Status)
Octreotide
(Sandostatin LAR)
10 mg
20 mg
30 mg
(Novartis)
(F)(PFL)1
preservative106
Oxaliplatin
50 mg
100 mg
(Sanofi-Aventis)
(RT)
no preservative108

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
2 mL supplied
diluent
10 mg: 5 mg/mL
20 mg: 10 mg/mL
30 mg: 15 mg/mL
discard unused
portion1
deep intragluteal
administration only1

initial reconstitution1,16
5 mg/mL108
24 h F109
> 0.2 mg/mL
24 h F,108 6 h RT109
gently run 2 mL
down sides of the
vial; do NOT
disturb for 25
min, then swirl
moderately1
SWI, D5W:
50 mg: 10 mL
100 mg: 20 mL
do NOT use NS
or other chloridecontaining
solutions
(degrades)108
250500 mL D5W
do NOT use NS or
other chloridecontining solutions
(degrades)108
(may use
reconstitution
device)

21/33
Special
Precautions/Notes
- noncytotoxic10
- do NOT shake
- nonvesicant11
- latex-free**9
- cytotoxic3
- no overfill
- irritant11
- latex** content
not determined
DRUG & STRENGTH

Status)
Oxaliplatin
50 mg
100 mg
(Mayne)
(RT)
no preservative110
Oxaliplatin
50 mg
100 mg
(Sigmacon)
(RT)
no preservative111
Paclitaxel
30 mg/5 mL
100 mg/16.7 mL
300 mg/50 mL
(Biolyse)
(F) (may store at RT for
2 months)112
no preservative

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
SWI, D5W:
50 mg: 10 mL
100 mg: 20 mL
5 mg/mL110
discard unused
portion110
SWI, D5W:
50 mg: 10 mL
100 mg: 20 mL
- cytotoxic3
- irritant11
- latex** content
not determined
24 h F, 6 h RT111
- cytotoxic3
- irritant11
- latex** content
not determined
do NOT use NS or
(degrades)110
5 mg/mL111
24 h F111
500 mL D5W
do NOT use NS or
(degrades)111
do NOT use NS
solutions
(degrades)111
N/A
48 h F110
> 0.2 mg/mL

250 500 mL D5W
do NOT use NS
solutions
(degrades)110
Special
Precautions/Notes
6 mg/mL112

8 h RT112
0.31.2 mg/mL in NS,

D5W112
24 h RT112
(e.g., 1001000 mL)*
22/33
- cytotoxic3
- use non-PVC bag
and tubing with inline filter112
- irritant11
- latex** content
not determined
DRUG & STRENGTH

Status)
Paclitaxel
30 mg/5 mL
100 mg/16.7 mL
300 mg/50 mL
(BMS)
(RT)(PFL)
no preservative113
Pamidronate
30 mg/10 mL
60 mg/10 mL
90 mg/10 mL
(Mayne)
(RT)
no preservative114

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
N/A
6 mg/mL113
3 mg/mL
6 mg/mL
9 mg/mL114
30 mg: 48 h
RT16,113
100 mg: 48 h
RT16,113
300 mg: 24 h
0.31.2 mg/mL in NS,

D5W, D5-NS, D5 in
Ringers113
discard unused
portion114
0.060.36 mg/mL
NS, D5W114
24 h RT113
(e.g.,1001000 mL)*
Special
Precautions/Notes
- cytotoxic3
- irritant11
- use non-PVC and
tubing with in-line
filter113
- latex-free**9
24 h F followed by 24
h RT (total 48 h)114
- noncytotoxic116
- protect from
light114
- nonvesicant4
- latex-free**9
24 h F, RT117
- cytotoxic3
- overfill117
- nonvesicant4
- latex** content
not determined

initial
reconstitution16,119
- noncytotoxic3
- overfill118
- irritant11
- latex-free**9,119
do NOT mix with

calcium containing
solution (e.g.,
Ringers)114
e.g., 250 mL NS115
Pemetrexed
500 mg
(Eli Lilly)
(RT)
no preservative117
Porfimer
15 mg
75 mg
(Axcan)
(RT)(PFL)
no preservative118
20 mL NS117
25 mg/mL117
24 h F, RT117
dilute with NS to total

volume 100 mL78,117
do NOT mix with
calcium containing
solution (e.g.,
Ringers)117
6.6 mL D5W
31.8 mL D5W118
2.5 mg/mL118

24 h F
(PFL)118
syringe118
23/33
DRUG & STRENGTH

Status)
Raltitrexed
2 mg
(AstraZeneca)
(F, RT)(PFL)
no preservative120
Rituximab
100 mg/10 mL
500 mg/50 mL
(Roche)
(F)(PFL)
no preservative62
Streptozocin
1g
(Pfizer)
(F)(PFL)
no preservative121
Teniposide
15 mg/1.5 mL
(Bristol)
preservative1

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
4 mL SWI120
0.5 mg/mL120
24 h F, RT120
50250 mL NS,
D5W120
24 h F, RT120
N/A
10 mg/mL62
discard unused
portion62
14 mg/mL in NS,
D5W)62
24 h F + additional 12
h RT62
Special
Precautions/Notes
- cytotoxic3
- nonvesicant11
- latex-free**9
- noncytotoxic3
- nonvesicant11
- latex-free**9
(e.g., 500 mg/250

mL, 1000 mg/500
mL)*
9.5mL NS, SWI,
D5W 121
N/A
100 mg/mL121
10 mg/mL1
48 h F,121 24 h
RT
discard unused
portion1
syringe121
48 h F, 24 h RT121
50-500 mL* NS,

D5W, SWI121
48 h F, 24 h RT121
0.1, 0.2, 0.4, or 1

mg/mL in NS or
D5W1
0.1, 0.2, 0.4mg/mL: 24

h RT
1 mg/mL: complete
administration within 4
h1

24/33
- cytotoxic3
- vesicant11
- latex-free**9
- cytotoxic3
- do NOT
refrigerate1
- use non-PVC
equipment1
- irritant11
- latex-free9
DRUG & STRENGTH

Status)
Thiotepa
15 mg
(Bedford)
(F)(PFL)
no preservative122
Thiotepa
IT injection:
15 mg
(Bedford)
(F)(PFL)
no preservative122

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
1.5 mL SWI122
10 mg/mL122
8 h F122
> 50 mL* NS122

initial
reconstitution16,122
- cytotoxic3
- filter through 0.22
micron filter before
administration122
- nonvesicant11
- latex** content
not determined
diluents
containing
preservatives
should NOT be
used for
intrathecal
administration
2 mg/mL solution2
use
immediately122
qs to 6 mL with
preservative free
NS49

initial
reconstitution16,49,122
- auxiliary label50 :
IT
- label to include
INTRATHECAL
to both syringe and
outer ziplock bag50
- cytotoxic3
- filter through 0.22
micron filter before
administration122
- nonvesicant11
- latex** content
not determined
1 mg/mL123
24 h F, RT123
0.020.5 mg/mL
24 h F, RT123
- cytotoxic3
- nonvesicant11
- latex-free**9
7.5 mL NS2
Topotecan
4 mg
(GSK)
(RT)(PFL)
no preservative123
Special
Precautions/Notes
4 mL SWI123

50100 mL NS,
D5W123
25/33
DRUG & STRENGTH

Status)
Trastuzumab
440 mg
(Roche)
(F)
preservative124
Vinblastine
10 mg/10 mL
(Mayne)
(F)(PFL)
no preservative24
Vincristine
1 mg/1 mL
2 mg/2 mL
5 mg/5 mL
(Mayne)
(F)(PFL)
no preservative127

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
20 mL supplied
BWI
21 mg/mL124
14 d F76,124
N/A
24 h F, RT124
- noncytotoxic3
- do NOT shake124
- nonvesicant11
- latex** content
not determined
syringe2,24
48 h F125
100250 mL NS,
D5W126
14 d F: NS17,125
- cytotoxic3
- auxiliary label (for
syringe only):
Warning: FATAL if
given
intrathecally24
- vesicant11
- latex-free**48
syringe: qs to 20 mL
with NS in 30 mL
syringe*
48 h RT, 7 d F2,16,128
do NOT use dextrose

containing
solutions124
swirl vial gently;

allow to stand
undisturbed for 5
min124
N/A
250mL NS124
1 mg/mL24
1 mg/mL 127
24 h F, RT125
8 h F, RT127
- cytotoxic3
syringe only):
Warning: FATAL if
given intrathecally
127
50 mL* NS, D5W

Special
Precautions/Notes
127
24 h F, 6 h RT,
26/33
127
- protect from
light127
- vesicant11
- latex-free**48
DRUG & STRENGTH

Status)
Vincristine
1 mg/1 mL
2 mg/2 mL
5 mg/5 mL
(Novopharm)
(F)(PFL)
preservative31
Vinorelbine
10 mg/1 mL
50 mg/5 mL
(GSK)
(F)(PFL)
no preservative129
Vinorelbine
10 mg/1 mL
50 mg/5 mL
(Mayne)
(F)(PFL)

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
N/A
1 mg/mL31
14 d F, RT31
syringe: qs to 20 mL
with NS in 30 mL
syringe*
48 h RT, 7 d F2,16,128
Special
Precautions/Notes
- cytotoxic3
syringe only):
Warning: FATAL if
given intrathecally
31
50 mL* NS, D5W31
72 h F, 24 h RT31
- protect from
light31
- vesicant11
- latex-free**9
N/A
10 mg/mL129
discard unused
portion129
syringe: 1.5 3.0

mg/mL in NS or
D5W129
24 h F, RT129
- cytotoxic3
syringe only):
Warning: FATAL if
given
intrathecally129
- vesicant11
- latex-free**94
N/A
10 mg/mL130
discard unused
portion130
syringe: 1.5 3.0

mg/mL in NS or
D5W130
24 h F, RT130
- cytotoxic3
syringe only):
Warning: FATAL if

27/33
DRUG & STRENGTH

Status)
no preservative130

Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
0.5 2.0 mg/mL129,130
24 h F, RT130
50 mL* NS, D5W,

NS, D5NS,
Ringers, Ringers
Lactate130
Special
Precautions/Notes
given
intrathecally129
- vesicant11
- latex** content
not determined
* Suggested volume based on usual dose range and any concentration range of stability data
** Latex free means the product does not contain natural rubber latex in its packaging or is packaged as plastic (e.g., Polyamps) and glass ampoules 9
Note: As of January 2006, this table has been formulated based on a low risk classification when preparations are made according to current policies,
directives and standards of practice.
Explanatory Notes
Vial stability: Stability of solution after first puncture or reconstituted solution
Storage temperature: If information states same stability with refrigerator and room temperature storage, then bold refrigerated as preferred
Cytotoxic: hazardous (see Policy II-20 for more details).
Discard unused portion: Unused portion from single use vials are assumed to discarded at the end of the day.
If information states same stability with refrigerator and room temperature storage, then bold refrigerated as preferred (ie, to minimize growth of microorganisms).
State overfill known if the manufactuerer states overfill within acceptable limits is present.
PFL = protect from light

RT = room temperature
F = refrigerated
SWI = sterile water for injection
NS = normal saline
D5W = dextrose 5%
BWI = bascteriostatic water for injection
28/33

29/33
References
1. Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
2. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
3. National Institute for Occupational Safety and Health (NIOSH). Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Healthcare
Settings. Cincinnati, OH; 25 March 2004.
4. BC Cancer Agency. Systemic Therapy Policy III-20: Extravasation of Chemotherapy, Prevention and Management of. Vancouver, British Columbia: BC Cancer
Agency; 1 September 2006.
5. Schering AG. MabCampath Package Leaflet. Berlin, Germany; April 2002.
6. Berlex Canada Inc. Campath Drug Information. San Antonio, TX; Undated.
7. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004(18):484-90.
8. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for the treatment of fludarabine-refractory B-chronic lymphocytic leukemia (B-CLL) and Tprolymphocytic leukemia (T-PLL) with alemtuzumab (ULYALEM). Vancouver, British Columbia: BC Cancer Agency; 01 July 2006.
9. Latex allergy and parenteral products. In: Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists
Association; 2004. p. L93-5.
10. MedImmune Pharma B.V. Ethyol Package Insert. The Netherlands; 2003.
11. BC Cancer Agency. Systemic Therapy Policy III-20: Extravasation of Chemotherapy, Prevention and Management of. Vancouver, British Columbia: BC Cancer
Agency; 1 July 2006.
12. Emmanuelle Laflamme, B.Pharm. Personal communication. Medical Information Officer, Amsacrine, Pfizer. February 2005.
13. OPi SAS. Kidrolase Product Monograph. Laval, Quebec; 2003.
14. Robert Sarrazin, B Pharm. Personal communication. Consultant, OPi Inc. February 2005.
15. Rhone-Poulenc Rorer. Kidrolase Package Insert. Montreal; 2004.
16. BC Cancer Agency Lymphoma Tumour Group. BCCA Protocol summary for the treatment of Multiple Myeloma with Bortezomib. Vancouver: BC Cancer Agency;
UMYBORTEZ, 2005.
17. United States Pharmacopeia (USP). (797) Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: UPS Convention, Inc.; 2004.
18. Repchinsky C, editor. ImmuCyst monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005.
19. Organon Teknika Corporation. OncoTICE Product Monograph. Durham, North Carolina; January 1998.
20. Roche. Bevacizumab for injection, Summary product information. Mississauga; 2005.
21. Repchinsky C, editor. Blenoxane monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005.
22. Faulding (Canada) Inc. Bleomycin Product Monograph. Montreal, Quebec; 3 June 2002.
23. Sheila Ahmed. Personal communication Bleomycin. Regulatory Affairs Associate, Bleomycin, Mayne Pharma Canada 2004;July 2, 2004(Ref JUN-128-2004,).
24. Mayne Pharma (Canada) Inc. Latex-free products. Montreal, Quebec; Feb 8, 2005.
25. Millenium Pharmaceuticals Inc. Velcade product monograph. Cambridge, Massachusetts; May 2003.
26. Walker S, Milliken D, Law S. Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4C and room temperature (23C). Canadian Journal of
Hospital Pharmacy 2006;59 (Suppl 1):62.
27. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6
January 2006.
28. Janssen-Ortho Inc. Velcade product monograph. Toronto,Ontario; 18 April, 2006.
29. Orphan Medical I. Busulfex Package Insert. Flamborough, Ontario; August 1999.
30. Mayne Pharma (Canada) I. Carboplatin Package Insert. Montreal, QC; Undated.
30/33
31. Novopharm Limited. Vincristine product monograph. Scarbough, Canada; 1999.

32. Repchinsky C, editor. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
33. Bristol Laboratories of Canada. BiCNU Package Insert. Montreal, Canada; 2002.
34. Bristol-Myers Squibb. Quality Assurance. Montreal; February 2005.
35. Bristol-Myers Squibb. Erbitux(Cetuximab) Prescribing Information. 2004.
36. Mayne Pharma (Canada) Inc. Cisplatin Package Insert. Montreal, QC; Undated.
37. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
38. Repchinsky C, editor. Cisplatin CPhA monograph, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association;
2004.
39. Mayne Pharma (Canada) Inc. Cisplatin injection. Montreal, Quebec; 12 October, 2005.
40. Janssen-Ortho Inc. Leustatin Package Insert. North York, Ontario; 1998.
41. Oryx Pharmaceuticals Inc. Clasteon Product Monograph. Mississauga, Ontario; 25 November 2004.
42. Bristol-Myers Squibb Canada. Cytoxan Product Monograph. Montral Canada; 2004.
43. Baxter Corporation. Procytox Package Insert. Missisauga, Ontario; 1 October 2003.
44. Paul Agro. Personal communication. Medical Information, etoposide, Baxter. 12 July, 2006.
45. Baxter Corporation. Procytox Package Insert. Toronto, Ontario; 2004.
46. Faulding (Canada) Inc. Cytarabine Package Insert. Montreal, QC; Undated.
47. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. cytarabine injection - stability information 2005;# OCT-612005(October 17, 2005).
48. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. fluorouracil 2005;reference # FEB-43-2005(february 16, 2005).
49. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for solid tumours using intrathecal methotrexate and/or thiptepa and/or
cytarabine (MOIT). Vancouver, British Columbia: BC Cancer Agency; 2005.
50. BC Cancer Agency. Systemic Therapy Policy III-50: Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir.
Vancouver, British Columbia: BC Cancer Agency; 31 October 2002.
51. Yamina Chikhaoui, BPharm, PhD. Personal communication. Medical Information, Pfizer Canada. February 2005.
52. Mayne Pharma (Canada) Inc. Methotrexate Product Monograph. Montreal, QC; 2003.
53. Mayne Pharma (Canada) Inc. Dacarbazine Package Insert. Montreal, QC; 2004.
54. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. dacarbazine 2005;#FEB-14-2005(february 8, 2005).
55. Merck & CO. Inc. Cosmegen Package Insert. Whitehouse Station, NJ; December 2002.
56. Ernest Pregent. Personal Communication. Director Medical Services Merck Frosst, 2005;November 1, 2005.
57. Merck Frosst Canada. Personal communication. Medical Information, Dactinomycin, Merck Frosst Canada. February 2005.
58. Sam Jatoe. Personnal communication. Regulatory Affairs Associate, Daunorubicin, Novopharm. February 2005.
59. Pharmacia & Upjohn Inc. Zinecard Package Insert. Mississauga, Ontario; 2004.
60. Pharmacia & Upjohn Company. Zinecard: US Prescribing Information. Kalamazoo, MI; 2003 September.
61. Emmanuelle Laflamme, B.Pharm. Personal communication. Medical Information Officer, Dexrazoxane, Pfizer. February 2005.
62. Hoffmann-La Roche Limited. Rituxan Package Insert. Mississauga, Ontario; December 2002.
63. Aventis Pharma Inc. Taxotere Package Insert. Laval (Quebec) Canada; 2004.
64. Mayne Pharma (Canada) Inc. Doxorubicin Package Insert. Montreal, QC; Undated.
65. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, QC; 2002.
66. John Korontzis. Personal communication. Regulatory Affairs Associate, Doxorubicin, Mayne Pharma Canada. February 2005.
67. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996.
31/33
68. Schering Canada Inc. Caelyx Package Insert. Pointe-Claire, Quebec; September 2001.
69. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003.
70. Bristol Laboratories of Canada. Vepesid Package Insert. Montreal, Canada; March 2000.
71. Nicole Hojm, Kinda Karra. Personal communication. Medical Information, etoposide, Bristol-Myers Squibb. February 2005.
72. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000.
73. Berlex Canada Inc. Fludara Package Insert. Lachine, Quebec; December 1998.
74. Mayne Pharma (Canada) Inc. Fluorouracil Package Insert. Montreal, Quebec; Undated.
75. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy
1989;46(10):2036-40.
76. BC Cancer Agency. Guiding Principles for Chemotherapy Preparation Chart. Policy Number II-20 2005.
77. Eli Lilly Canada Inc. Gemzar Package Insert. Toronto, Ontario; 16 January 2002.
78. Marilyn Bain, BSc N. Personal communication. Sr Therapeutic Area Specialist Medical Information, Pemetrexed. October 21, 2005 2005.
79. Pharmacia & Upjohn Inc. Idamycin Package Insert. Mississauga, Ontario; July 1997.
80. BC Cancer Agency. revised Guiding Principles for Chemotherapy Preparation Chart. Policy Number II-30 2005.
81. Emmanuelle Laflamme, BPharm. Personal communication. Medical Information Officer, Idarubicin, Pfizer. February 2005.
82. Baxter Corporation. Ifex Package Insert. Toronto, Ontario; Undated.
83. Schering Canada Inc. Intron A Package Insert. Pointe-Claire, Quebec; January 2003.
84. Julie Lacasse, BScN RN. Personal communication. Associate Medical Information, Schering. February 2005.
85. Edward Kavalec, Schering Canada - Medical Services. Intron A (interferon alpha-2b). 2006.
86. Schering Canada. Intron A Product Monograph. Pointe Claire Quebec; December 2004.
87. Mayne Pharma (Canada) Inc. Iritnotecan Package Insert. Montreal, QC; 28 April 2005.
88. Beryl Chan. Personal communication. Mayne Pharma (Canada) Inc. Scientific Affairs Manager, Irinotecan. 2 February 2006.
89. Pharmacia Canada Inc. Camptosar Package Insert. Mississauga, Ontario; May 2002.
90. Faulding (Canada) Inc. Leucovorin Package Insert. Montreal, QC; Undated.
91. John Korontzis. Personal communication. Regulatory Affairs Associate, Leucovorin Calcium, Mayne Pharma Canada. February 2005.
92. Merck Frosst Canada & CO. Mustargen Package Insert. Kirkland, Quebec; 2 May 1994.
93. GlaxoSmithKline Inc. Alkeran Package Insert. Mississauga, Ontario; Montreal, Quebec; 2004.
94. GlaxoSmithKline. Summary of the rubber-containing components of GlaxoSmithKline products. February 2005.
95. Pharmaceutical Partners of Canada Inc. Mesna Package Insert. Richmond Hill, Ontario; November 2001.
96. John Korontzis. Personal communication. Regulatory Affairs Associate, Methotrexate, Mayne Pharma Canada. February 2005.
97. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Methotrexate, Vincristine, Mayne Pharma Canada. 14 March 2005.
98. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for treatment of leptomeningeal lymphoma or recurrent intracerebral lymphoma with high
dose methotrexate (LYHDMTXR). Vancouver, British Columbia: BC Cancer Agency; 1 June 2004.
99. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for treatment of meningeal disease (miscellaneous tumour origins) using high
dose methotrexate with leucovorin rescue (UMOHDMTX). Vancouver, British Columbia: BC Cancer Agency; 21 September 1999.
100. BC Cancer Agency Sarcoma Tumour Group. BCCA protocol summary for treatment of osteosarcoma using high dose methotrexate with leucovorin rescue
(OSHDMTX). Vancouver, British Columbia: BC Cancer Agency; 1 August 2000.
101. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for treatment of primary intracerebral lymphoma with high dose methotrexate
(LYHDMTXP). Vancouver, British Columbia: BC Cancer Agency; 1 June 2004.
102. Sam Jatoe. Personal communication. Regulatory Affairs Associate, Mitomycin, Novopharm. February 2005.
103. Bristol Laboratories of Canada. Mutamycin Package Insert. Montreal, Canada; 2000.
32/33
104. Wyeth Canada. Novantrone Package Insert. Montreal, Canada; October 2003.
105. Faulding (Canada) Inc. Mitoxantrone Package Insert. Montreal, Quebec; 2002.
106. Repchinsky C, editor. Sandostatin LAR monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005.
107. Vancouver Hospital and Health Sciences Centre Pharmacy Department. Octreotide. In: Parenteral drug therapy manual. Vancouver, BC; February 2002.
108. Sanofi-Synthelabo Oncology. Eloxatin Summary of Product Characteristics. Markham, Ontario; August 2001.
109. Sanofi-Synthelabo Inc. Eloxatin Prescribing Information. Bedford, OH; January 2004.
110. Mayne Pharma Plc. Oxaliplatin Mayne for injection. Royal Leamington Spa, Warwickshire, United Kingdom; 9 March 2006.
111. Sigmacon Lifesciences. Oxaliplatin for injection. North York, ON; January 2006.
112. Biolyse Pharma. Paclitaxel Package Insert. Ontario, Canada; November 2002.
113. Bristol-Myers Squibb Canada. Taxol Package Insert. Montreal, Canada; September 2002.
114. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
115. BC Cancer Agency Breast Tumour Group. BCCA protocol summary for treatment of acute bone pain secondary to breast cancer metastases using pamidronate or
IV clodronate (BRAVPAM). Vancouver, British Columbia: BC Cancer Agency; 1 May 2001.
116. Novartis Pharmaceuticals Corporation. Aredia Product Monograph. East Hanover, New Jersey,; 2003.
117. Eli Lilly Canada Inc. ALIMTA Product Monograph. Toronto, Ontario; 21 May 2004.
118. Axcan Pharma Inc. Photofrin Package Insert. Mont-Saint-Hilaire, Quebec; 2004.
119. Marie-Helene Doyon, B.Pharm., M.Sc. Personal communication. Medical Information Specialist, Porfimer, Axcan Pharma. 3 March 2005.
120. AstraZeneca. Tomudex Package Insert. Mississauga, Ontario; November 2001.
121. Pharmacia Canada Inc. Zanosar Package Insert. Mississauga, Ontario; March 2003.
122. Bedford Laboratories. Thiotepa Package Insert. Bedford, Ohio, U.S.A.; April 2001.
123. GlaxoSmithKline. Hycamtin Package Insert. Mississauga, Ontario; Montreal, Quebec; 2001.
124. Hoffmann-La Roche Limited. Herceptin Package Insert. Mississauga, Ontario; October 2002.
125. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. vinblastine 2005;#Feb-52-2005(february 17, 2005).
126. Repchinsky C, editor. Vinblastine CPhA monograph, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association;
2004.
127. Mayne Pharma (Canada) Inc. Vincristine Package Insert. Montreal, QC; Undated.
128. Trissel LA, Zhang Y, Cohen MR. The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hospital Pharmacy
2001;36(7):740-5.
129. GlaxoSmithKline Inc. Navelbine Package Insert. Mississauga, Ontario; Montreal, Quebec; Undated.
130. Mayne Pharma (Canada) Inc. Vinorelbine Product Monograph. Montreal, QC; Undated.

33/33

ChemoStabilityChart 1sep06 Rev2 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ChemoStabilityChart 1sep06 Rev2 PDF

Uploaded by

Copyright:

Available Formats

DRUG & STRENGTH

(Storage Prior to Use,

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

do not shake; roll

1.2 mL SWI only1

2550 mL* NS only10

use 5 micron filter to

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

500 mL D5W only1

do not shake; roll

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

do not shake; roll

transfer from vial to

do not shake; roll

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

50 mL* NS, SWI22

use 5-micron nylon

BC Cancer Agency Chemotherapy Preparation and Stability Chart

250 mL* NS, D5W2,30

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

may be further diluted

250 mL* NS,

3.3 mg/mL in 10%

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

< 60 mg: 100 NS*

500 or 1000 mL* NS,

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

< 1 g: 100 NS*

NS,2 D5W, D5NS,

< 1 g: 100 NS*

NS,2 D5W, D5NS43

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

use within 4 hours of

100 mg: 20 mg/mL

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

200 mg: 19.7 mL

empty viaflex bag59

500 mL* NS or D5W

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

NS, SWI, D5W64

100 mL* NS64

BC Cancer Agency Chemotherapy Preparation and Stability Chart

DRUG & STRENGTH